The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELVN | -39.21% | -72.61% | -22.79% | -26% |
| S&P | +12.65% | +91.73% | +13.89% | +69% |
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded in June 2019 and is headquartered in Boulder, CO.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.08M | -2.5% |
| Market Cap | $1.18B | 7.7% |
| Market Cap / Employee | $18.78M | -14.6% |
| Employees | 63 | 21.2% |
| Net Income | -$25.34M | -27.0% |
| EBITDA | -$28.50M | -16.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $119.44M | 23.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.38M | 122.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.12% | 2.8% |
| Return On Invested Capital | -25.67% | -4.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.20M | 15.9% |
| Operating Free Cash Flow | -$17.06M | 16.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.95 | 3.69 | 3.11 | 3.41 | -0.84% |
| Price to Tangible Book Value | 3.95 | 3.69 | 3.11 | 3.41 | -0.84% |
| Enterprise Value to EBITDA | -34.87 | -30.14 | -22.01 | -19.48 | -41.13% |
| Return on Equity | -31.0% | -32.0% | -31.3% | -25.3% | -10.95% |
| Total Debt | $0.09M | $0.00M | $0.37M | $0.38M | 122.49% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
